Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira® is a registered trademark of AbbVie Biotechnology Ltd.
Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira® is a registered trademark of AbbVie Biotechnology Ltd.
October 10, 2019
London, UK
ISOPP
International Society of Oncology Pharmacy Practicioners, October 10 - 13 2019
October 09, 2019
Madrid, Spain
EADV
European Academy of Dermatology and Venerology, October 9 - 13 2019
October 08, 2019
Hong Kong, China
PENSA
The Parenteral and Enteral Nutrition Society of Asia, October 8 - 10 2019
September 27, 2019
Barcelona, Spain
ESMO
European Society for Medical Oncology, September 27 - October 1 2019
September 25, 2019
Krakow, Poland
EUGMS
International Congress of the European Geriatric Medicine Society, September 25 - 27 2019
Leucovorin Calcium is the newest addition to the company’s large oncology portfolio.
September 19, 2019
Vienna, Austria
ESSD
European Society for Swallowing Disorders, September 19 - 21 2019
August 31, 2019
Krakow, Poland
ESPEN
European Society for Clinical Nutrition and Metabolism, August 31 - September 3 2019